Key Takeaways
- Wegovy is FDA-approved for chronic weight management in adults and children 12+ with obesity, and for reducing cardiovascular events in adults with overweight or obesity plus established cardiovascular disease.
- Eligibility for the weight indication: BMI 30+, or BMI 27+ with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnea.
- The active ingredient is semaglutide, the same molecule in Ozempic, but at a higher target dose (2.4 mg weekly).
- In the STEP 1 trial (Wilding et al., NEJM 2021), patients on Wegovy lost an average of 14.9% of body weight over 68 weeks.
- The SELECT trial (Lincoff et al., NEJM 2023) showed Wegovy reduced major cardiovascular events by 20% in adults with cardiovascular disease and overweight or obesity, even without diabetes.
Direct answer (40-60 words)
Wegovy is FDA-approved for chronic weight management in adults and adolescents 12+ with obesity, and for reducing the risk of cardiovascular death, heart attack, and stroke in adults with overweight or obesity who have established cardiovascular disease. It contains semaglutide and is administered as a once-weekly subcutaneous injection.
Table of contents
- The 30-second answer
- The two FDA-approved uses
- Who is eligible for Wegovy
- How Wegovy works
- The dosing schedule
- Expected weight loss results
- Cardiovascular benefits beyond weight loss
- Off-label and emerging uses
- Side effects and contraindications
- How Wegovy compares to Ozempic
- FAQ
- Sources
The two FDA-approved uses
Wegovy has two FDA-approved indications. Each was approved at a different time and based on different clinical trial evidence.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Indication 1: Chronic weight management. Approved in June 2021 for adults with obesity (BMI 30+) or with overweight (BMI 27+) plus at least one weight-related comorbidity. Expanded in December 2022 to adolescents 12 and older with obesity. The basis for approval was the STEP 1, STEP 2, STEP 3, and STEP 4 trial program, which showed average body weight loss of 14.9% over 68 weeks at the 2.4 mg dose, compared with 2.4% on placebo.
Indication 2: Cardiovascular risk reduction. Approved in March 2024 for adults with overweight or obesity plus established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease). The basis was the SELECT trial (Lincoff AM et al., NEJM 2023), which followed 17,604 adults for an average of 39.8 months and showed a 20% reduction in the composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke.
These are the only two indications the FDA has approved. Other uses (improving fertility outcomes, treating non-alcoholic fatty liver disease, addressing alcohol use disorder, and others) are under investigation but not approved.
Who is eligible for Wegovy
Eligibility for the weight management indication requires meeting one of these BMI criteria:
| Criterion | Required threshold |
|---|---|
| Adult obesity | BMI 30 or higher |
| Adult overweight with comorbidity | BMI 27 or higher AND at least one weight-related condition |
| Adolescent (12 to 17) obesity | BMI at or above the 95th percentile for age and sex |
Qualifying weight-related comorbidities for the BMI 27-29 group include:
- Type 2 diabetes
- High blood pressure (hypertension)
- High cholesterol (dyslipidemia)
- Obstructive sleep apnea
- Cardiovascular disease (also qualifies for the second indication)
- Polycystic ovary syndrome (PCOS)
- Non-alcoholic fatty liver disease
Eligibility for the cardiovascular risk-reduction indication requires:
- Adult age (18+)
- BMI 27 or higher
- Established cardiovascular disease (history of heart attack, stroke, or peripheral artery disease)
Wegovy is contraindicated in patients with:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to semaglutide or any pen excipients
- Pregnancy (Wegovy is not recommended during pregnancy)
A provider evaluation is required to determine whether a specific patient is a good candidate, regardless of whether the BMI numbers fit.
How Wegovy works
Wegovy's active ingredient is semaglutide, a synthetic version of the natural human hormone GLP-1 (glucagon-like peptide-1). It activates GLP-1 receptors throughout the body and produces three main effects.
Slows gastric emptying. Food sits in the stomach longer, extending the feeling of fullness after meals. Normal gastric emptying half-time is around 90 minutes; on Wegovy it can extend to 2 to 3 hours.
Reduces appetite via brain receptors. GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety. Wegovy activation of these receptors reduces hunger between meals and the brain's reward response to food cues. Patients commonly describe a quieting of "food noise."
Improves insulin response. Wegovy increases insulin secretion and decreases glucagon secretion in response to elevated blood sugar. This is helpful for patients with type 2 diabetes or prediabetes but doesn't cause hypoglycemia in patients with normal blood sugar regulation.
The combined effect is a daily caloric intake reduction of typically 500 to 1,200 calories, sustained over months. That deficit is what produces the weight loss documented in clinical trials.
The cardiovascular benefits in the SELECT trial occurred even after controlling for weight loss alone, suggesting Wegovy has direct effects on vascular inflammation, blood pressure, and other cardiovascular risk factors beyond just calorie reduction.
For a deeper look at the GLP-1 mechanism, see /articles/mechanism-and-science/what-does-semaglutide-do/.
The dosing schedule
Wegovy is administered as a once-weekly subcutaneous injection. The dose is escalated gradually over 16 to 20 weeks to allow the body to adapt and to minimize gastrointestinal side effects.
| Week | Weekly dose |
|---|---|
| 1-4 | 0.25 mg |
| 5-8 | 0.5 mg |
| 9-12 | 1.0 mg |
| 13-16 | 1.7 mg |
| 17+ | 2.4 mg (maintenance) |
Some patients can't tolerate the maintenance dose due to nausea or other GI effects. In those cases, the provider may keep the patient at 1.7 mg or even 1.0 mg as a longer-term dose. The 2.4 mg dose produces the best weight-loss outcomes but is not required for benefit. Even the 1.0 mg dose produces meaningful weight loss in most patients.
The pen is a single-dose auto-injector (not a multidose pen like Ozempic). Each pen contains one weekly dose. Injections are given in the abdomen, thigh, or upper arm, with site rotation each week.
For step-by-step injection instructions, see /articles/injection-technique/how-to-use-wegovy-pen/.
Expected weight loss results
The headline number from STEP 1 (Wilding et al., NEJM 2021) is 14.9% body weight loss at 68 weeks on the 2.4 mg dose. Underneath that average, the distribution looks like this:
| Weight loss achieved | Percentage of patients on Wegovy 2.4 mg | Percentage on placebo |
|---|---|---|
| 5% or more | 86.4% | 31.5% |
| 10% or more | 69.1% | 12.0% |
| 15% or more | 50.5% | 4.9% |
| 20% or more | 32.0% | 1.7% |
So roughly half of patients lose 15% or more of their starting body weight at 68 weeks. About a third lose 20% or more. A small minority (under 15%) lose less than 5%, typically because of dose intolerance or other factors.
Time course matters. Most weight loss happens during the first 12 months. Weight tends to plateau in months 13 through 18, with a small additional loss possible. The plateau is the new effective set point for that patient on that dose. Increases in dose can sometimes restart loss, but the response is variable.
If treatment is discontinued, weight tends to return. STEP 4 (Rubino DM et al., JAMA 2021) randomized patients who'd lost weight on semaglutide to either continue or switch to placebo. The continued group maintained loss; the placebo-switched group regained two-thirds of their lost weight within 48 weeks. This is consistent with what would be expected when an appetite-suppressing medication is removed.
Cardiovascular benefits beyond weight loss
The SELECT trial (Lincoff AM et al., NEJM 2023) is one of the most consequential cardiology trials of the past decade. It tested whether Wegovy could reduce cardiovascular events in patients with established cardiovascular disease and overweight or obesity, but without diabetes.
Trial structure: 17,604 adults randomized to Wegovy 2.4 mg or placebo, followed for an average of 39.8 months. The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke.
Results: 6.5% of Wegovy patients had a primary endpoint event, vs 8.0% on placebo. That's a 20% relative risk reduction (hazard ratio 0.80, 95% CI 0.72-0.90). The number needed to treat over the trial period was 67, meaning treating 67 patients for an average of 39.8 months prevents one major cardiovascular event.
Important nuance: the cardiovascular benefit was statistically separate from the weight loss. Patients who lost less weight still saw cardiovascular protection. This suggests Wegovy has direct effects on the vascular system beyond what would be expected from caloric restriction alone, possibly through anti-inflammatory effects, blood pressure reduction, or improved endothelial function.
The clinical implication: Wegovy may be a reasonable consideration for cardiovascular protection even in patients who aren't primarily seeking weight loss, if they meet the criteria.
Off-label and emerging uses
Beyond the two FDA-approved indications, Wegovy is being studied for several other conditions. None of these are approved, and prescribing for these uses would be off-label.
Non-alcoholic steatohepatitis (NASH). A phase 2 trial (Newsome et al., NEJM 2021) showed semaglutide produced significantly higher rates of NASH resolution compared with placebo. Phase 3 trials are ongoing. The FDA approved another GLP-1 (resmetirom) for NASH in 2024, suggesting the regulatory pathway is open.
Alcohol use disorder. Reduced alcohol cravings have been reported as a frequent off-label observation by patients on GLP-1 medications. A phase 2 trial (Klausen et al., 2024) showed semaglutide reduced heavy drinking days. Phase 3 trials are underway.
Polycystic ovary syndrome (PCOS). PCOS often involves insulin resistance and is associated with weight gain. Several small studies show semaglutide improves PCOS metabolic parameters and may improve fertility outcomes, though it's not currently FDA-approved for this use.
Knee osteoarthritis. The STEP 9 trial (Bliddal et al., NEJM 2024) showed semaglutide reduced knee pain in patients with obesity and knee osteoarthritis, with the benefit attributable to weight loss.
Chronic kidney disease. The FLOW trial (Perkovic et al., NEJM 2024) showed semaglutide reduced kidney disease progression in type 2 diabetics. Whether the benefit extends to non-diabetics is being studied.
Sleep apnea. Data from the SURMOUNT-OSA trial showed reductions in apnea-hypopnea index, though that trial used tirzepatide rather than semaglutide.
These represent the next likely waves of FDA approval over the next 2 to 5 years. None should be considered current standard-of-care indications today.
Side effects and contraindications
The most common side effects of Wegovy are gastrointestinal:
- Nausea (44% of patients in STEP 1)
- Diarrhea (32%)
- Vomiting (24%)
- Constipation (24%)
- Abdominal pain (20%)
Most GI effects are mild to moderate, occur during titration, and resolve as the body adapts. About 7% of patients in STEP 1 discontinued the medication due to side effects.
Less common but significant side effects:
- Acid reflux and heartburn (related to slowed gastric emptying)
- Headache and fatigue (especially during dose escalation)
- Injection-site reactions (small redness, itching)
- Hair loss (about 3% of patients, usually temporary)
- Gallstones and gallbladder disease (rare but more common with rapid weight loss)
- Pancreatitis (rare, requires immediate evaluation if severe abdominal pain)
Serious contraindications:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of severe pancreatitis
- Severe gastrointestinal disease
For management of common GLP-1 side effects, see /articles/side-effects/glp1-side-effect-management/.
How Wegovy compares to Ozempic
Both contain semaglutide. The differences:
| Feature | Wegovy | Ozempic |
|---|---|---|
| FDA-approved use | Weight management; cardiovascular risk reduction | Type 2 diabetes; cardiovascular risk reduction in diabetes |
| Maximum dose | 2.4 mg weekly | 2.0 mg weekly |
| Pen type | Single-dose auto-injector | Multidose pen with dose dial |
| Insurance coverage | Often covered for obesity if criteria met | Usually covered for diabetes |
| Cost without insurance | Around $1,350/month | Around $1,000/month |
Practically, the active ingredient is the same molecule, the mechanism is identical, and the side effect profile is similar. The dose ceiling differs because the weight-management indication targets a higher dose for stronger appetite suppression.
When prescribed off-label, Ozempic at 2.0 mg behaves similarly to Wegovy at 2.0 mg. The 2.4 mg ceiling is unique to Wegovy.
For the difference between brand-name and compounded options, see /articles/cost-and-insurance/wegovy-vs-compounded-semaglutide/.
FAQ
What is Wegovy used for? Wegovy is FDA-approved for two uses: chronic weight management in adults and children 12+ with obesity, and reducing the risk of major cardiovascular events in adults with overweight or obesity plus established cardiovascular disease.
Is Wegovy the same as Ozempic? The active ingredient is the same (semaglutide), but Wegovy goes up to 2.4 mg weekly while Ozempic tops out at 2.0 mg. Wegovy is FDA-approved for weight management; Ozempic is approved for type 2 diabetes.
Who qualifies for Wegovy? Adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity (such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or PCOS). Adolescents 12-17 with obesity also qualify. Adults with cardiovascular disease and BMI 27+ qualify under the second indication.
How much weight can I expect to lose on Wegovy? The average weight loss in STEP 1 was 14.9% of starting body weight over 68 weeks at the 2.4 mg dose. About half of patients lose 15% or more. About a third lose 20% or more. Results vary based on adherence, diet, exercise, and individual response.
How quickly does Wegovy work? Appetite changes typically begin within the first 1 to 2 weeks. Measurable weight loss usually starts around weeks 4 to 6. Most weight loss happens during the first 12 months, with plateau in months 13 to 18.
Do I need to take Wegovy forever? For chronic weight management, Wegovy is typically a long-term medication. STEP 4 showed that patients who discontinued regained two-thirds of their lost weight within 48 weeks. Treatment duration should be discussed with your provider based on individual response and goals.
Does Wegovy reduce heart attack risk? Yes, in patients with established cardiovascular disease. The SELECT trial showed a 20% reduction in cardiovascular death, non-fatal heart attack, or non-fatal stroke over an average of 39.8 months. The benefit was independent of weight loss.
Can I drink alcohol on Wegovy? You can, but many patients report dramatically reduced alcohol cravings while on Wegovy. Heavy drinking can worsen GI side effects, especially during titration. Talk with your provider if you have concerns.
Will my insurance cover Wegovy? Coverage varies. Some insurance plans cover Wegovy for obesity if criteria are met. Medicare doesn't currently cover Wegovy for weight loss alone but may cover it for cardiovascular risk reduction in patients with established disease. Check with your specific plan.
What if Wegovy isn't available or affordable? Compounded semaglutide may be an alternative for patients without coverage, though it's not FDA-approved. Other GLP-1 medications (Ozempic off-label, tirzepatide) may also be options. Discuss alternatives with your provider.
Can teenagers take Wegovy? Yes. Wegovy was FDA-approved for adolescents 12 to 17 with obesity in December 2022, based on the STEP TEENS trial which showed a 16.1% reduction in BMI over 68 weeks compared with 0.6% on placebo.
What's the difference between Wegovy and tirzepatide? Wegovy contains semaglutide, which activates only the GLP-1 receptor. Tirzepatide (sold as Zepbound and Mounjaro) activates both GLP-1 and GIP receptors. Tirzepatide produces somewhat larger weight loss in head-to-head data (about 20% vs 15% body weight reduction).
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
- Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3). JAMA. 2021;325(14):1403-1413.
- Rubino DM, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
- Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine. 2021;384:1113-1124.
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine. 2024;391:109-121.
- Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). New England Journal of Medicine. 2024;391:1573-1583.
- Weghuber D, et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). New England Journal of Medicine. 2022;387:2245-2257.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.